Israel’s largest medical center has developed AI that can predict whether patients with Crohn’s Disease require a specific kind of therapy to treat their condition.
Sheba Medical Center, near Tel Aviv, has demonstrated in a new study that its deep learning model achieved an accuracy of 81 percent when predicting whether patients are in need of biological therapy, a type of treatment that is made from living cells and is generally prescribed for Crohn’s Disease patients when other therapies have not worked.
The AI was more accurate than gastroenterologists, who normally determine whether patients need biological therapy through a capsule endoscopy, a procedure that uses a tiny wireless camera to take pictures of the digestive tract.
This is because every capsule film produces approximately 10,000 to 12,000 images for interpretation. Due to the large amount of visual information in each video, it is difficult for a doctor to discern all necessary details.
The AI, on the other hand, successfully scanned the film of 101 Crohn’s Disease patients, requiring only several minutes for each patient.
This research followed a trial last year, in which the AI algorithm demonstrated it could scan a film of up to 12,000 images in approximately two minutes. Additionally, the research found AI to be a highly effective diagnostic tool, producing 86 percent accuracy in image and data analysis compared to 68 percent accuracy achieved with the reliance on analysis by an experienced gastroenterologist.
“Predicting disease course and patient outcomes for Crohn’s Disease is one of the most critical clinical challenges in inflammatory bowel disease treatment,” says Prof. Uri Kopylov, director of IBD (Inflammatory bowel disease) in the Department of Gastroenterology at Sheba, who led the study.
“However, this research highlights the potential impact of AI on this process,” he said.
“By adopting AI in clinical practice, we can begin to use our wealth of knowledge and research in personalized medicine to drive improved patient outcomes and open the door to new possibilities for diagnosis and treatment.”
The study was published in the Therapeutic Advances in Gastroenterology journal.
Facebook comments